1095 related items for PubMed ID: 18071030
21. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
J Neurol Sci; 2010 May 15; 292(1-2):28-35. PubMed ID: 20236661
[Abstract] [Full Text] [Related]
22. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C.
J Neurol Sci; 2012 Jan 15; 312(1-2):97-101. PubMed ID: 21880336
[Abstract] [Full Text] [Related]
23. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
[Abstract] [Full Text] [Related]
24. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R.
Eur Neurol; 2004 Feb 04; 51(1):15-20. PubMed ID: 14631124
[Abstract] [Full Text] [Related]
25. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
Arch Neurol; 2005 Dec 04; 62(12):1843-7. PubMed ID: 16344342
[Abstract] [Full Text] [Related]
26. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E, Marchi P, Floris G, Mascia MG, Deriu M, Sirca A, Mamusa E, Lai M, Mura M, Mallarini G, Marrosu MG.
Funct Neurol; 2006 Dec 04; 21(3):145-9. PubMed ID: 17049133
[Abstract] [Full Text] [Related]
27. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
Neurol Sci; 2005 Dec 04; 26 Suppl 4():S174-8. PubMed ID: 16388353
[Abstract] [Full Text] [Related]
28. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A.
Acta Neurol Scand; 2006 Apr 04; 113(4):241-7. PubMed ID: 16542163
[Abstract] [Full Text] [Related]
29. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
Mult Scler; 2007 May 04; 13(4):490-501. PubMed ID: 17463072
[Abstract] [Full Text] [Related]
30. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA, Rivera VM.
Curr Med Res Opin; 2010 Apr 04; 26(4):827-38. PubMed ID: 20121658
[Abstract] [Full Text] [Related]
31. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
Mult Scler; 2010 Jan 04; 16(1):68-77. PubMed ID: 19995846
[Abstract] [Full Text] [Related]
32. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
Mult Scler; 2012 Aug 04; 18(8):1125-34. PubMed ID: 22194217
[Abstract] [Full Text] [Related]
33. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.
Wu X, Kuusisto H, Dastidar P, Huhtala H, Nikkari ST, Ukkonen M, Höyhtyä M, Elovaara I.
Acta Neurol Scand; 2007 Jul 04; 116(1):43-8. PubMed ID: 17587254
[Abstract] [Full Text] [Related]
34. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
Lancet Neurol; 2010 Jul 04; 9(7):672-80. PubMed ID: 20542736
[Abstract] [Full Text] [Related]
35. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.
J Neurol; 2003 Sep 04; 250(9):1037-43. PubMed ID: 14504963
[Abstract] [Full Text] [Related]
36. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleås F, Pedersen T, Bjørnarå B, Dalene F, Kleveland G, Schepel J, Olsen IC, Myhr KM.
Arch Neurol; 2012 Aug 04; 69(8):1044-51. PubMed ID: 22507886
[Abstract] [Full Text] [Related]
37. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N, Filippi M, Hawkins C, 9011 study group.
J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
[Abstract] [Full Text] [Related]
38. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
Lancet Neurol; 2009 Jun 15; 8(6):519-29. PubMed ID: 19409854
[Abstract] [Full Text] [Related]
39. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
Rudick RA, Kappos L, Kinkel R, Clanet M, Phillips JT, Herndon RM, Sandrock AW, Munschauer FE.
Mult Scler; 2011 Mar 15; 17(3):353-60. PubMed ID: 20965959
[Abstract] [Full Text] [Related]
40. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
Zhao Y, Traboulsee A, Petkau AJ, Li D.
Neurology; 2008 Mar 25; 70(13 Pt 2):1092-7. PubMed ID: 18003938
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
